Optimal management of the patient with chronic atrial fibrillation: Whom to cardiovert?

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 3, 1999, Pages 442-448

  Miller, John M ^a   Jayachandran, J Vijay ^a   Coppess, Mark A ^a   Olgin, Jeffrey E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; WARFARIN;

CARDIOVERSION; CONFERENCE PAPER; DEFIBRILLATION; DRUG EFFECT; DRUG INDUCED DISEASE; FLUOROSCOPY; HEART ATRIUM FIBRILLATION; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SINUS RHYTHM; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 0033064172     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00698.x     Document Type: Conference Paper

References (57)

1. Halpern JL, Hart RG: Atrial fibrillation and stroke: New ideas, persisting dilemmas. Stroke 1988;19:937-941.
2. van Gelder IC, Crijns HJ, Tieleman RG, et al: Chronic atrial fibrillation: Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996;156:2585-2592.
3. Kerin NZ, Faitel K, Naini M: The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: Amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med 1996;156:49-53.
4. Franz MR, Karasik PL, Li C, et al: Electrical remodeling of the human atrium: Similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997;30:1785-1792.
5. Jovic A, Troskot R: Recovery of atrial systolic function after pharmacological conversion of chronic atrial fibrillation to sinus rhythm: A Doppler echocardiographic study. Heart 1997;77:46-49.
6. Danias PG, Caulfield TA, Weigner MJ, et al: Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998;31:588-592.
7. Kannel WB, Abbott RD, Savage DD, et al: Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982;306:1018-1022.
8. Atwood JE, Myers J, Sullivan M: The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J 1989;118:913-918.
9. Lipkin DP, Frenneaux M, Stewart R, et al: Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J 1988;59: 572-577.
10. Tse HF, Lau CP: Is there a role for cardioversion of very chronic atrial fibrillation by transvenous atrial defibrillation? J Am Coll Cardiol 1998;31:332A.
11. Olsson SB, Öhrdahl G, Eneström S, et al: Spontaneous reversion from long-lasting atrial fibrillation to sinus rhythm. Acta Med Scand 1980;207:5-20.
12. Gregori F, Cordeiro CO, Couto WJ, et al: Cox maze operation without cryoablation for the treatment of chronic atrial fibrillation. Ann Thorac Surg 1995;60: 361-363.
13. Yashima N, Nasu M, Kawazoe K, et al: Serial evaluation of atrial function by Doppler echocardiography after the maze procedure for chronic atrial fibrillation. Eur Heart J 1997;18:496-502.
14. Yuda S, Nakatani S, Yamagishi M, et al: Long-term follow-up of atrial contraction following the maze procedure in patients with mitral valvular disease. J Am Coll Cardiol 1998;31:152A.
15. Bjerkelund CJ, Orning OM: The efficacy of anticoagulant therapy in preventing embolism related to DC cardioversion of atrial fibrillation. Am J Cardiol 1969; 23:208-215.
16. Arnar DO, Danielsen R: Factors predicting maintenance of sinus rhythm after after direct current cardioversion of atrial fibrillation and flutter: A reanalysis with recently acquired data. Cardiology 1996;87:181-188.
17. Alt E, Ammer R, Lehmann G, et al: Patient characteristics and inderlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. Am Heart J 1997;134:419-425.
18. Henry WL, Morganroth J, Pearlman AS, et al: Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976;53: 273-279.
19. Volgman AS, Soble JS, Neumann A, et al: Effect of left atrial size on recurrence of atrial fibrillation after electrical cardioversion: Atrial dimension versus volume. Am J Card Imaging 1996;10:261-265.
20. Kay GN, Bubien RS, Epstein AE, et al: Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1998;62:741-744.
21. Brignole M, Gianfranchi L, Menozzi C, et al: Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994;74:242-246.
22. Greenberg ML, Malenka DJ, Disch DL: Therapeutic strategies for atrial fibrillation: The value of decision analysis. Cardiol Clin 1996;14:623-640.
23. Lawson-Matthew PJ, Ionescu A, McHugh P, et al: Evaluation of a protocol to select patients of all ages for cardioversion from atrial fibrillation. Age Ageing 1997; 26:247-252.
24. Manning WJ, Leeman DE, Gotch PJ, et al: Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989;13:617-623.
25. Shapiro EP, Effron MB, Lima S, et al: Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. Am J Cardiol 1988;62:1202-1207.
26. Manning WJ, Silverman DI, Katz SE, et al: Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994;23:1535-1540.
27. Black IW, Fatkin D, Sagar KB, et al: Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 1994;89: 2509-2513.
28. Page RL, Wilkinson WE, Clair WK, et al: Asymptomatic arrhythmias in patients with symtomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994;89:224-227.
29. Duytschaever M, Haerynck F, Tavernier R, et al: Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. PACE 1998;21:284-287.
30. Foster RH, Wilde MI, Markham A: Ibutilide: A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997;54:312-330.
31. Volgman AS, Carberry PA, Stambler B, et al: Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31: 1414-1419.
32. Opolski G, Stanislawska J, Gorecki A, et al: Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. Clin Cardiol 1997;20: 337-340.
33. Tieleman RG, Gosselink AT, Crijns HJ, et al: Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997;79:53-57.
34. Bianconi L, Mennuni M, Lukie V, et al: Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study. J Am Coll Cardiol 1996;28:700-706.
35. Stroobandt R, Stiels B, Hoebrechts R: Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997;79:418-423.
36. Kerber RE: Transthoracic cardioversion of atrial fibrillation and flutter: Standard techniques and new advances. Am J Cardiol 1996;78:22-26.
37. Bjerregaard P, Janosik DL, Schiller L, et al: Double external shocks for refractory atrial fibrillation. J Am Coll Cardiol 1997;29:474A.
38. Levy S, Lacombe P, Cointe R, et al: High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol 1988;12:514-518.
39. Murgatroyd FD, Slade AK, Sopher SM, et al: Efficacy and tolerability of transvenous low energy cardioversion of paroxsmal atrial fibrillation in humans. J Am Coll Cardiol 1995;25:1347-1353.
40. van Gelder IC, Crijns HJGM, van Gilst WH, et al: Effect of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989;63:112-114.
41. Manning WJ, Silverman DI, Katz SE, et al: Electrical vs pharmacologic cardioversion for atrial fibrillation: Differential effect on return of left atrial mechanical function. Circulation 1994;90:1-541.
42. Abascal VM, Dubrey S, Ochoa MR, et al: Electrical vs pharmacologic cardioversion in atrial fibrillation: Does the atrium really care? Circulation 1995;92:I-591.
43. Upshaw CB: Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997;157:1070-1076.
44. Van Gelder IC, Crijns HJ: Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm. PACE 1997;20:2675-2683.
45. Echt DS, Liebson PR, Mitchell LB, et al: Mortality and morbidity in patients receiving encainide, flecainide, or placebo - The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
46. Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-532.
47. Prystowsky EN: Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol 1994;17:7-10.
48. Maisel WH, Kuntz KM, Reimold SC, et al: Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997;127:281-284.
49. Chun SH, Sager PT, Stevenson WG, et al: Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
50. Halinen MO, Huttunen M, Paakkinen S, et al: Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 1995;76:495-498.
51. Hohnloser SH, Li YG: Drug treatment of atrial fibrillation: what have we learned? Curr Opin Cardiol 1997; 12:24-32.
52. Fresco C, Proclemer A: Clinical challenge. II. Management of recent onset atrial fibrillation. PAFIT-2 Investigators. Eur Heart J 1996;17:41-47.
53. Crijns HJ, Gosselink AT, Lie KI: Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther 1996;10:145-152.
54. Antman EM, Beamer AD, Cantillon C, et al: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-707.
55. Crijns HJ, van Gelder IC, van der Woude HJ, et al: Efficacy of serial electrical cardioversion theraphy in patients with chronic atrial fibrillation after valve replacement and implications for surgery to cure atrial fibrillation. Am J Cardiol 1996;78:1140-1144.
56. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine theraphy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
57. Altamura G, Bianconi L, Lo Bianco F, et al: Transthoracic DC shock may represent a serious hazard in pacemaker dependent patients. PACE 1995;18: 194-198.